You just read:

Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ (CPX-351) Significantly Improved Overall Survival

News provided by

Celator Pharmaceuticals, Inc.

06 Jun, 2016, 07:00 ET